New drugs and combinations for the treatment of soft-tissue sarcoma: a review.

A separate update of the SMAC meta-analysis including this EORTC study with a total of 2170 patients, presented by O’Connor et al, showed a benefit of adjuvant chemotherapy for disease-free and overall survival after 5 years, but only a nonsignificant trend toward improved survival after 10 years (OR 0.87, P = 0.12). 7 A pooled analysis of individual patient data from the two largest adjuvant trials conducted by EORTC 6 , 8 using doxorubicin- and ifosfamide-based chemotherapy was also presented the same year and did not show a survival advantage for p

also in 5,406 other papers

A recent press release from Ziopharm reported a positive trend in OS favoring the palifosfamide arm, with an HR of 0.79 in the intention-to-treat population.

also in 11,005 other papers

OS showed a trend toward improvement, but was not statistically significant (median 12.5 versus 10.7 months; HR = 0.86 [95% CI 0.67–1.11]).

also in 53,322 other papers